DE69535495D1 - Expression und exporttechnologie von proteinen als an immunoglobin gebundene fusionsproteine - Google Patents

Expression und exporttechnologie von proteinen als an immunoglobin gebundene fusionsproteine

Info

Publication number
DE69535495D1
DE69535495D1 DE69535495T DE69535495T DE69535495D1 DE 69535495 D1 DE69535495 D1 DE 69535495D1 DE 69535495 T DE69535495 T DE 69535495T DE 69535495 T DE69535495 T DE 69535495T DE 69535495 D1 DE69535495 D1 DE 69535495D1
Authority
DE
Germany
Prior art keywords
expression
target protein
proteins
protein
immunoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535495T
Other languages
English (en)
Other versions
DE69535495T2 (de
Inventor
Kin-Ming Lo
Yukio Sudo
Stephen D Gillies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of DE69535495D1 publication Critical patent/DE69535495D1/de
Application granted granted Critical
Publication of DE69535495T2 publication Critical patent/DE69535495T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
DE69535495T 1994-09-14 1995-09-14 Expression und exporttechnologie von proteinen als an immunoglobin gebundene fusionsproteine Expired - Lifetime DE69535495T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/305,700 US5541087A (en) 1994-09-14 1994-09-14 Expression and export technology of proteins as immunofusins
US305700 1994-09-14
PCT/US1995/011720 WO1996008570A1 (en) 1994-09-14 1995-09-14 Expression and export technology of proteins as immunofusins

Publications (2)

Publication Number Publication Date
DE69535495D1 true DE69535495D1 (de) 2007-06-21
DE69535495T2 DE69535495T2 (de) 2008-01-17

Family

ID=23181945

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535495T Expired - Lifetime DE69535495T2 (de) 1994-09-14 1995-09-14 Expression und exporttechnologie von proteinen als an immunoglobin gebundene fusionsproteine

Country Status (11)

Country Link
US (2) US5541087A (de)
EP (1) EP0782625B1 (de)
JP (1) JP2877959B2 (de)
AT (1) ATE361985T1 (de)
AU (1) AU691980B2 (de)
CA (1) CA2199830C (de)
DE (1) DE69535495T2 (de)
DK (1) DK0782625T3 (de)
ES (1) ES2285706T3 (de)
PT (1) PT782625E (de)
WO (1) WO1996008570A1 (de)

Families Citing this family (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
JPH11505421A (ja) * 1995-05-11 1999-05-21 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒトウリジンジホスフェートガラクトース−４−エピメラーゼ
WO1997026911A1 (en) * 1996-01-29 1997-07-31 Georgetown University Malaria vaccine based upon the addition of a msa1 peptide
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
DK0914155T3 (da) * 1996-03-25 2006-06-26 Medarex Inc Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
WO1997040033A1 (en) * 1996-04-19 1997-10-30 Lexigen Pharmaceuticals Corp. Inhibition of the binding of human ige to its receptor by tetracyclic compounds for the alleviation of ige-mediated immune response
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20050003431A1 (en) * 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
ATE286120T1 (de) * 1996-09-13 2005-01-15 Transkaryotic Therapies Inc Therapie für alpha galactosidase a insuffizienz
US5968782A (en) * 1996-12-04 1999-10-19 Brigham And Womens's Hospital, Inc. Mast cell protease that cleaves fibrinogen
EP0963435B1 (de) 1997-01-08 2008-05-28 Invitrogen Corporation Verfahren zur herstellung von proteinen
US5955431A (en) * 1997-02-05 1999-09-21 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
US6852508B1 (en) * 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
NZ502745A (en) * 1997-07-21 2003-02-28 Pharmacia & Upjohn Ab Use of superantigen conjugates for the directed cytolysis of target cells
US20030027257A1 (en) * 1997-08-21 2003-02-06 University Technologies International, Inc. Sequences for improving the efficiency of secretion of non-secreted protein from mammalian and insect cells
US6037150A (en) * 1997-08-21 2000-03-14 University Technologies International Inc. Insect sequences for improving the efficiency of secretion of non-secreted proteins in eukaryotic cells
US20030022298A1 (en) * 1997-09-15 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020127584A1 (en) * 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166106A1 (en) * 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ATE267215T1 (de) 1997-12-08 2004-06-15 Lexigen Pharm Corp Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
PL343462A1 (en) * 1998-04-15 2001-08-13 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
WO1999058662A1 (fr) * 1998-05-14 1999-11-18 Merck Patent Gmbh Proteine fusionnee
CA2339331C (en) * 1998-08-25 2011-03-01 Lexigen Pharmaceuticals Corporation Expression and export of angiogenesis inhibitors as immunofusins
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
KR20020007287A (ko) * 1999-01-07 2002-01-26 추후보정 Ｆｃ 융합 단백질로서 항-비만 단백질의 발현 및 이출
AU3224700A (en) 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
KR100312456B1 (ko) 1999-03-13 2001-11-03 윤덕용 슈도모나스 플루오레슨스 유래의 외래단백질 분비촉진유전자
EP1187852B1 (de) * 1999-05-19 2007-08-08 EMD Lexigen Research Center Corp. Expression und export von interferon-alpha proteinen als fc fusionsproteine
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001008700A1 (en) * 1999-07-28 2001-02-08 Genetics Institute, Inc. Preventing immune-mediated abortion by inhibiting costimulation
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
EP1731531B1 (de) 1999-08-09 2012-05-30 Merck Patent GmbH Mehrere Zytokin-Antikörper Komplexe
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2001036489A2 (en) 1999-11-12 2001-05-25 Merck Patent Gmbh Erythropoietin forms with improved properties
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
US20030064950A1 (en) * 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
CA2402412A1 (en) * 2000-03-08 2001-09-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Human extracellular signal regulated kinases
EP1263957A2 (de) * 2000-04-05 2002-12-11 MERCK PATENT GmbH Humanisches lipid-bindungsprotein i
US20030176338A1 (en) * 2000-05-05 2003-09-18 Klaus Ducker Novel serine-threonine kinase
AU2001262996A1 (en) * 2000-05-08 2001-11-20 Georgetown University Malaria vaccine and methods thereof based upon novel antigenic domain of plasmodium falciparum
WO2001085937A2 (en) * 2000-05-12 2001-11-15 Merck Patent Gmbh Regulator of g protein signalling (rgs8)
ES2288967T3 (es) * 2000-06-29 2008-02-01 Merck Patent Gmbh Reforzamiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citoquina por medio del tratamiento combinado por agentes que mejoran la incorporacion de inmunocitoquina.
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
AU2002249521B2 (en) * 2001-01-16 2007-06-21 Serono Genetics Institute S.A. Discriminative nucleic acid analysis using clone sequence signatures
CA2440221C (en) * 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002078730A2 (en) 2001-03-28 2002-10-10 Biogen, Inc. Use of neublastin polypeptides for treating neuropathic pain
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1423519A2 (de) * 2001-08-27 2004-06-02 Novartis AG G-protein gekoppelter rezeptor und dazugehörige dns
US20030228298A1 (en) * 2001-09-04 2003-12-11 Mark Nesbit Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
US6800462B2 (en) * 2001-09-10 2004-10-05 Abgenomics Corporation Production of recombinant proteins in vivo and use for generating antibodies
US20030049694A1 (en) * 2001-09-10 2003-03-13 Chung-Hsiun Wu Production of fusion proteins and use for identifying binding molecules
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
ES2381025T3 (es) 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
ATE503845T1 (de) * 2001-12-10 2011-04-15 Novartis Pharma Gmbh Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
EP1488231A2 (de) 2002-03-19 2004-12-22 Novartis AG Nachweismethode für verbindungen die wirksam gegen chronische neuropathie-schmerzen sind und diesbezügliche zusammensetzungen
EP1576099A4 (de) * 2002-04-12 2007-07-11 Bristol Myers Squibb Co Neue, das menschliche citron-kinase-polypeptid bmsnkc 0020/0021 codierende polynukleotide
DE60328685D1 (de) 2002-06-13 2009-09-17 Merck Patent Gmbh Verfahren für die identifizierung von allo-antigenen und ihren verwendung für krebs therapie und transplantation
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US20040052777A1 (en) * 2002-09-04 2004-03-18 Mark Nesbit Kringle polypeptides and methods for using them to inhibit angiogenesis
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
ES2346205T3 (es) * 2002-12-17 2010-10-13 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticurpo 14.18 de raton que se enlaza con gd2 y su fusion con la il-2.
WO2004060041A2 (en) 2002-12-30 2004-07-22 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
JP2007501021A (ja) * 2003-05-30 2007-01-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 遺伝子操作された定常領域を含む、抗体および融合タンパク質
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
WO2005063820A2 (en) 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
CA2553883C (en) 2004-01-22 2013-04-02 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-cancer antibodies with reduced complement fixation
EP2053062A1 (de) * 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobinvarianten außerhalb der Fc-Region
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
EP2301963A1 (de) 2004-09-23 2011-03-30 Vasgene Therapeutics, Inc. Polypeptidverbindungen zur Hemmung von Angiogenese und Tumorwachstum
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2314618A3 (de) 2004-11-12 2011-10-19 Xencor Inc. Fc-Varianten mit modifizierter Bindung an FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DE602005020837D1 (de) * 2004-12-09 2010-06-02 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CA2595169A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
WO2006089231A2 (en) 2005-02-18 2006-08-24 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
US7566456B2 (en) * 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
BRPI0616118A2 (pt) * 2005-09-01 2011-06-07 Ares Trading Sa tratamento de neurite ótica
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
JP2009509564A (ja) * 2005-10-03 2009-03-12 アストラゼネカ・アクチエボラーグ 血漿中半減期が調節された融合タンパク質
CA2624189A1 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2625998C (en) 2005-10-06 2015-12-01 Xencor, Inc. Optimized anti-cd30 antibodies
CA2634262A1 (en) * 2005-12-22 2007-07-05 Dhy & Co., Ltd Antibodies against interleukin-22 binding protein and its uses
CA2635618C (en) * 2005-12-30 2015-10-06 Merck Patent Gesellschaft Mit Beschraekter Haftung Interleukin-12p40 variants with improved stability
PT2270050E (pt) 2005-12-30 2013-09-12 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
WO2007088051A2 (en) 2006-01-31 2007-08-09 Bayer Schering Pharma Aktiengesellschaft Modulation of mdl-1 activity for treatment of inflammatory disease
JP2009531324A (ja) 2006-03-20 2009-09-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
EA020805B1 (ru) 2006-05-24 2015-01-30 Мерк Сероно С.А. Применение комбинации кладрибина и бета-интерферона для лечения рассеянного склероза
EP2038417A2 (de) * 2006-07-06 2009-03-25 Merck Patent GmbH Zusammensetzungen und verfahren zur verstärkung der wirksamkeit von il-2-vermittelten immunreaktionen
EP2069386A4 (de) 2006-07-21 2009-10-28 Life Technologies Corp Proteinmolekülgewichtsstandards mit hoher trennschärfe
DK2383297T5 (da) 2006-08-14 2022-07-04 Xencor Inc Optimerede antistoffer rettet mod CD19
CA2660795C (en) * 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
BRPI0718283A2 (pt) * 2006-10-20 2013-11-12 Biogen Idec Inc Tratamento de distúrbios desmielinizantes
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
KR20170012582A (ko) 2006-11-02 2017-02-02 악셀레론 파마 인코포레이티드 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
TW200907056A (en) * 2007-03-28 2009-02-16 Astrazeneca Ab New method
US8492118B2 (en) 2007-05-11 2013-07-23 Altor Bioscience Corporation Fusion molecules and IL-15 variants
CN105131127B (zh) 2007-05-30 2018-09-07 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
ES2742268T3 (es) 2007-12-26 2020-02-13 Xencor Inc Variantes de Fc con unión alterada a FcRn
EP2283040A2 (de) 2008-05-02 2011-02-16 Acceleron Pharma, Inc. Auf alk1-antagonisten basierende methoden und zusammensetzungen zur modulierung der angiogenese und der pericytenauflagerung
EP2352763B2 (de) 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispezifischer einzelkettenantikörper mit spezifität für hochmolekulare target-antigene
KR101026526B1 (ko) * 2009-01-23 2011-04-01 한국과학기술연구원 대장균에서 외래단백질을 분비 생산하는 방법
WO2010096486A1 (en) 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
AU2010238858A1 (en) * 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
WO2010148010A1 (en) 2009-06-15 2010-12-23 4S3 Bioscience Inc. Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
KR101061017B1 (ko) * 2009-10-23 2011-08-31 (주) 수파드엘릭사 암세포의 성장 및/또는 전이 억제용 약학 조성물
RU2673908C2 (ru) 2009-12-02 2018-12-03 Имэджинэб, Инк. Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
CN102947341B (zh) 2010-01-19 2018-07-06 哈佛大学校长及研究员协会 用于病原体检测和治疗的工程化调理素
EP2536756B1 (de) 2010-02-16 2018-04-25 MedImmune, LLC Mit hsa zusammenhängende zusammensetzungen und verwendungsverfahren
US20130231464A1 (en) 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
ES2826445T3 (es) * 2010-04-28 2021-05-18 Oncolmmune Inc Uso médico de CD24 soluble
JP5953303B2 (ja) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
CA2811734C (en) 2010-09-21 2021-11-23 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
EP2505640A1 (de) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
AU2012245439B2 (en) 2011-04-20 2017-04-06 Acceleron Pharma, Inc. Endoglin polypeptides and uses thereof
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
CN105189542A (zh) 2013-02-20 2015-12-23 瓦莱里昂治疗有限责任公司 用于治疗庞贝氏症的方法和组合物
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CA3093606A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
JP2016521283A (ja) 2013-05-06 2016-07-21 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 成長因子モジュレーションのための組成物および方法
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
WO2015061666A1 (en) 2013-10-25 2015-04-30 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
EP3077048B1 (de) 2013-12-07 2019-07-17 Case Western Reserve University Zusammensetzungen und verfahren zur behandlung von thrombose
US10221250B2 (en) 2014-01-13 2019-03-05 Valerion Therapeutics, Llc Internalizing moieties
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
SG10202008629XA (en) 2014-03-28 2020-10-29 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
AU2015269333B2 (en) 2014-06-04 2020-05-07 Acceleron Pharma, Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
ES2899890T3 (es) 2014-06-30 2022-03-15 Altor Bioscience Corp Moléculas basadas en IL-15 y métodos de uso de las mismas
WO2016022597A1 (en) 2014-08-04 2016-02-11 Case Western Reserve University Targeting peptides and methods of use
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
LT3223845T (lt) 2014-11-26 2021-08-25 Xencor, Inc. Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EA037065B1 (ru) 2014-11-26 2021-02-01 Ксенкор, Инк. Гетеродимерные антитела, связывающие cd3 и cd38
EP3237449A2 (de) 2014-12-22 2017-11-01 Xencor, Inc. Trispezifische antikörper
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
DK3280432T3 (da) 2015-04-06 2021-04-26 Subdomain Llc Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf
WO2016197018A1 (en) 2015-06-05 2016-12-08 Ibio, Inc. Endostatin fragments and variants for use in treating fibrosis
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
AU2016304764C1 (en) 2015-08-07 2023-06-01 Imaginab, Inc. Antigen binding constructs to target molecules
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
CN117362450A (zh) 2016-05-27 2024-01-09 阿尔托生物科学有限公司 具有cd3结合域的基于多聚体il-15的分子的构造和表征
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CA3029328A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
BR112019007920A2 (pt) 2016-10-21 2019-10-08 Altor Bioscience Corp moléculas multiméricas à base de il-15
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CN110785435B (zh) 2017-03-06 2024-01-23 艾尔特生物科技公司 与il-12和il-18的基于il-15的融合物
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
ES2948647T3 (es) 2017-05-04 2023-09-15 Acceleron Pharma Inc Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas
CN110799206A (zh) * 2017-05-22 2020-02-14 肿瘤免疫股份有限公司 使用可溶性cd24治疗癌症疗法中免疫相关不良事件的方法
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
US11161890B2 (en) 2017-08-28 2021-11-02 Altor Bioscience LLC. IL-15-based fusions to IL-7 and IL-21
WO2019094637A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MX2020004933A (es) 2017-11-14 2021-01-08 Arcellx Inc Polipéptidos que contienen dominios d y sus usos.
SG11202003168WA (en) 2017-11-14 2020-05-28 Arcellx Inc Multifunctional immune cell therapies
AU2018366480C1 (en) * 2017-11-17 2024-02-01 Grifols Diagnostic Solutions Inc. Novel mammalian expressed human immunodeficiency virus envelope protein antigens
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
TW202003011A (zh) 2018-03-26 2020-01-16 美商艾爾特生物科技責任有限公司 抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3781598A1 (de) 2018-04-18 2021-02-24 Xencor, Inc. Auf tim-3 abzielende heterodimere fusionsproteine mit il-15-/il-15ra-fc-fusionsproteinen und tim-3-antigen-bindenden domänen
CN110964116A (zh) 2018-09-26 2020-04-07 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
KR20210134725A (ko) 2019-03-01 2021-11-10 젠코어 인코포레이티드 Enpp3과 cd3에 결합하는 이종이량체 항체
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4219533A1 (de) * 2020-09-28 2023-08-02 Korea Research Institute of Chemical Technology Rekombinanter mikroorganismus mit polynukleotid, das ein zielproduktbindendes protein codiert, das an eine sekretionssignalsequenz fusioniert ist, zusammensetzung damit und verfahren zur herstellung eines zielprodukts damit
KR102625766B1 (ko) * 2020-09-28 2024-01-17 한국화학연구원 분비 신호서열에 융합된 표적산물 결합 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물, 그를 포함하는 조성물 및 그를 이용하여 표적산물을 생산하는 방법
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0234592A1 (de) * 1986-02-28 1987-09-02 Teijin Limited Plasmid, das ein DNA-Fragment enthält, welches für die Fc-Region von menschlichem Immunoglobulin G Protein codiert, und Verwendung desselben zur Herstellung des genannten Proteins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE144793T1 (de) * 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
ATE218889T1 (de) * 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
CA2095842A1 (en) * 1990-11-09 1992-05-10 Stephen D. Gillies Bridging antibody fusion constructs
US6072039A (en) * 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
WO1993003157A1 (en) * 1991-07-29 1993-02-18 Dana Farber Cancer Institute Plasmids for the rapid preparation of modified proteins
AU689214B2 (en) * 1994-02-01 1998-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Fusion proteins that include antibody and nonantibody portions
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US7344304B2 (en) 2005-06-14 2008-03-18 Varian Medical Systems Technologies, Inc. Self-alignment of radiographic imaging system

Also Published As

Publication number Publication date
US5541087A (en) 1996-07-30
WO1996008570A1 (en) 1996-03-21
JP2877959B2 (ja) 1999-04-05
ATE361985T1 (de) 2007-06-15
CA2199830A1 (en) 1996-03-21
EP0782625A1 (de) 1997-07-09
DE69535495T2 (de) 2008-01-17
EP0782625B1 (de) 2007-05-09
AU691980B2 (en) 1998-05-28
PT782625E (pt) 2007-08-20
US5726044A (en) 1998-03-10
JPH10505751A (ja) 1998-06-09
ES2285706T3 (es) 2007-11-16
DK0782625T3 (da) 2007-08-06
AU3676595A (en) 1996-03-29
CA2199830C (en) 2003-05-06

Similar Documents

Publication Publication Date Title
DE69535495D1 (de) Expression und exporttechnologie von proteinen als an immunoglobin gebundene fusionsproteine
SE8107812L (sv) Rekombinerade dna-molekyler och forfaranden for framstellning av proteiner
DE68905633D1 (de) Markierer der t-zelle aktivierung.
LU90591I2 (fr) Enbrel-etanercept
DK0542863T3 (da) Ekspression af rekombinante polypeptider med forbedret oprensning
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
HUP9800730A2 (hu) Expressziós rendszer heterológ antigének fúziós proteinként történő expresszáltatására
DE3382760D1 (de) Herstellung von funktionellen menschlichen Urokinasepolypeptiden.
DE69632658D1 (de) Expression in der selben Zelle von Polypeptide vom schweinen reproduktiven und respiratorischen Syndrom
EP0686161A4 (de) Alpha untereinheit des humanen beta-2 integrins
FI922204A (fi) Proteinkomplex med faktor viii:c- aktivitet och framstaellning av desamma.
DE59611434D1 (de) Herstellung von Proteinen aus Pro-Proteinen durch Fusionsproteine abgeleitet von Furin oder Furinanalogen
ATE109829T1 (de) Interleukin-7.
PT755447E (pt) Proteinas recombinantes de hemaglutinina filamentosa de bordetella particularmente bordetella pertussis metodo para a sua producao e suas aplicaoes na producao de proteinas estranhas ou de principios activos para vacinas
ATE150791T1 (de) Proteinstruktur des pflanzlichen toxins gelonin
NO911557L (no) Fremgangsmaate for fremstilling av fremmedproteiner i streptomyceter.
FI945877A (fi) Menetelmä proteiini C:n tuottamiseksi
ATE229983T1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
IT8521507A0 (it) Vettore di clonaggio, molecole di dna ricombinante, ceppi di bacillus subtilis trasformati con dette molecole e metodi per l'espressione di geni eterologhi e produzione e secrezione di proteine codificate da detti geni.
ATE312185T1 (de) Sequenzen zur verbesserung der sekretionseffizienz von nicht-sekretierten proteinen in säugetier- und insektenzellen
DK0592574T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner og værtsceller anvendt derved

Legal Events

Date Code Title Description
8364 No opposition during term of opposition